guest ::
| Home > In process > [18F]FDG-PET/CT Imaging for Response Characterisation of Experimental Melanomas to Anti-PD-L1/Anti-CTLA-4 Immunotherapy. > print |
| Home > In process > [18F]FDG-PET/CT Imaging for Response Characterisation of Experimental Melanomas to Anti-PD-L1/Anti-CTLA-4 Immunotherapy. > print |
| 001 | 284041 | ||
| 005 | 20260120143902.0 | ||
| 024 | 7 | _ | |a 10.1007/s11307-025-02056-7 |2 doi |
| 024 | 7 | _ | |a pmid:41102571 |2 pmid |
| 024 | 7 | _ | |a 1536-1632 |2 ISSN |
| 024 | 7 | _ | |a 1860-2002 |2 ISSN |
| 037 | _ | _ | |a DZNE-2026-00076 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Antons, Melissa J |0 0000-0002-2668-360X |b 0 |
| 245 | _ | _ | |a [18F]FDG-PET/CT Imaging for Response Characterisation of Experimental Melanomas to Anti-PD-L1/Anti-CTLA-4 Immunotherapy. |
| 260 | _ | _ | |a Cham |c 2025 |b Springer Nature Switzerland |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1768916251_9457 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Immune checkpoint inhibition has shown promising results in malignant melanoma, but not all patients respond equally well, necessitating early, accurate monitoring of immunotherapy response. [18F]FDG-PET/CT aids in characterising therapy response beyond morphology, but validated imaging biomarkers for immunotherapy response remain scarce. This study investigated three-time point [18F]FDG-PET/CT to monitor combined anti-PD-L1/anti-CTLA-4 immunotherapy in murine melanoma allografts and compared quantitative in vivo imaging biomarkers with ex vivo biomarkers from multiparametric immunohistochemistry at each time point.Melanoma cells (B16-F10) were injected subcutaneously into C57BL/6 mice (n = 40). Seven days post-inoculation, baseline [18F]FDG-PET/CT was conducted. Animals were randomized into two groups; the therapy group received 5 i.p.-injections of anti-PD-L1/anti-CTLA-4 (20 µg/kg) on days 7, 9, 11, 13 and 15 after tumor cell inoculation. The control group received sham treatment. PET/CT was performed at baseline (day 7 post inoculation), follow-up 1(day 13; FU-1) and follow-up 2 (day 19; FU-2). Tumor allografts were harvested at each time point for immunohistochemistry (CD8, Ki-67, TUNEL) to validate imaging parameters (MTV, SUVmax).At FU-1, the therapy group exhibited significantly lower MTV than the control group (p = 0.004). At FU-2, MTV and SUVmax were significantly lower (MTV: p = 0.008; SUVmax: p = 0.0003) compared to controls. Ex vivo analysis revealed significant anti-tumor effects in the therapy group, with higher apoptosis rates (FU-1: p = 0.012; FU-2: p = 0.001), more CD8-positive T-cells (FU-2: p = 0.003) and lower tumor cell proliferation (FU-1: p = 0.012; FU-2: p = 0.012).Multi-time point [18F]FDG-PET/CT allowed for early non-invasive monitoring of combined anti-PD-L1/anti-CTLA-4 immunotherapy in experimental melanomas, validated by multiparametric immunohistochemistry with significant pro-immunogenic, pro-apoptotic and anti-proliferative effects. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a Immunohistochemistry |2 Other |
| 650 | _ | 7 | |a Immunotherapy |2 Other |
| 650 | _ | 7 | |a Melanoma |2 Other |
| 650 | _ | 7 | |a [18F]FDG-PET/CT |2 Other |
| 650 | _ | 7 | |a Fluorodeoxyglucose F18 |0 0Z5B2CJX4D |2 NLM Chemicals |
| 650 | _ | 7 | |a CTLA-4 Antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a B7-H1 Antigen |2 NLM Chemicals |
| 650 | _ | 7 | |a Immune Checkpoint Inhibitors |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Positron Emission Tomography Computed Tomography |2 MeSH |
| 650 | _ | 2 | |a Fluorodeoxyglucose F18: chemistry |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy |2 MeSH |
| 650 | _ | 2 | |a CTLA-4 Antigen: antagonists & inhibitors |2 MeSH |
| 650 | _ | 2 | |a CTLA-4 Antigen: immunology |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 650 | _ | 2 | |a B7-H1 Antigen: antagonists & inhibitors |2 MeSH |
| 650 | _ | 2 | |a B7-H1 Antigen: immunology |2 MeSH |
| 650 | _ | 2 | |a Cell Line, Tumor |2 MeSH |
| 650 | _ | 2 | |a Melanoma, Experimental: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Melanoma, Experimental: therapy |2 MeSH |
| 650 | _ | 2 | |a Melanoma, Experimental: pathology |2 MeSH |
| 650 | _ | 2 | |a Melanoma, Experimental: immunology |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Immune Checkpoint Inhibitors: therapeutic use |2 MeSH |
| 650 | _ | 2 | |a Immune Checkpoint Inhibitors: pharmacology |2 MeSH |
| 700 | 1 | _ | |a Kloiber-Langhorst, Sandra |b 1 |
| 700 | 1 | _ | |a Hirner-Eppeneder, Heidrun |b 2 |
| 700 | 1 | _ | |a Schaefer, Rebecca |b 3 |
| 700 | 1 | _ | |a Stueckl, Jennifer |b 4 |
| 700 | 1 | _ | |a Palumbo, Giovanna |b 5 |
| 700 | 1 | _ | |a Oos, Rosel |b 6 |
| 700 | 1 | _ | |a Herr, Felix L |b 7 |
| 700 | 1 | _ | |a Lindner, Simon |b 8 |
| 700 | 1 | _ | |a Ziegler, Sibylle |b 9 |
| 700 | 1 | _ | |a Brendel, Matthias |0 P:(DE-2719)9001539 |b 10 |u dzne |
| 700 | 1 | _ | |a Ricke, Jens |b 11 |
| 700 | 1 | _ | |a Werner, Rudolf A |b 12 |
| 700 | 1 | _ | |a Heimer, Maurice M |b 13 |
| 700 | 1 | _ | |a Cyran, Clemens C |b 14 |
| 773 | _ | _ | |a 10.1007/s11307-025-02056-7 |g Vol. 27, no. 6, p. 1006 - 1014 |0 PERI:(DE-600)2079211-6 |n 6 |p 1006 - 1014 |t Molecular imaging & biology |v 27 |y 2025 |x 1536-1632 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/284041/files/DZNE-2026-00076_Restricted.pdf |
| 856 | 4 | _ | |u https://pub.dzne.de/record/284041/files/DZNE-2026-00076_Restricted.pdf?subformat=pdfa |x pdfa |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 10 |6 P:(DE-2719)9001539 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-20 |w ger |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2024-12-20 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-20 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-20 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL IMAGING BIOL : 2022 |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-20 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-20 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2024-12-20 |
| 920 | 1 | _ | |0 I:(DE-2719)1110007 |k AG Haass |l Molecular Neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a EDITORS |
| 980 | _ | _ | |a VDBINPRINT |
| 980 | _ | _ | |a I:(DE-2719)1110007 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|